SAFETY AND EFFICACY OF INSULIN GLARGINE/LIXISENATIDE AND INSULIN DEGLUDEC/INSULIN ASPART IN TYPE 2 DIABETES PATIENTS NOT CONTROLLED ON BASAL INSULIN: A NETWORK META-ANALYSIS

被引：0
|
作者：
Jammah, A. [1 ]
机构：
[1] King Saud Univ, Dept Endocrinol, Riyadh, Saudi Arabia
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2020年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
394
引用
收藏
页码：A185 / A186
页数：2
相关论文
共 50 条
  • [1] Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin
    Jammah, Anwar Ali
    PRIMARY CARE DIABETES, 2021, 15 (01) : 132 - 137
  • [2] Efficacy and Safety of Insulin Aspart 30 and Insulin Degludec/Aspart vs. Basal Insulin in Patients with Type 2 Diabetes: A Meta-analysis
    Mishriky, Basem M.
    Tanenberg, Robert J.
    Cummings, Doyle M.
    DIABETES, 2017, 66 : A252 - A252
  • [3] Efficacy and Safety of Insulin Degludec/Insulin Aspart versus Biphasic Insulin Aspart 30 in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
    Niu, Yan-Li
    Zhang, Ye
    Song, Zhi-Yong
    Zhao, Chuan-Zhi
    Luo, Yun
    Wang, Yan
    Yuan, Jing
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2024, 53 (02) : 313 - 322
  • [4] Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials
    Long, Tao
    Lin, Jin-ting
    Lin, Min-hua
    Wu, Qian-long
    Lai, Jian-mei
    Li, Sheng-zhen
    Zhou, Zi-chao
    Zeng, Ji-yuan
    Huang, Jia-shuan
    Zeng, Chun-ping
    Lai, Yao-ming
    ENDOCRINE JOURNAL, 2022, 69 (08) : 959 - 969
  • [5] Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
    Moon, Shinje
    Chung, Hye-Soo
    Kim, Yoon-Jung
    Yu, Jae-Myung
    Jeong, Woo-Ju
    Park, Jiwon
    Oh, Chang-Myung
    METABOLITES, 2021, 11 (09)
  • [6] Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) in Type 2 Diabetes: Systematic Review and Meta-Analysis
    Edina, Brenda C.
    Tandaju, Jeremy R.
    Wiyono, Lowilius
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [7] Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials
    Zhang, Xiao-Wen
    Zhang, Xin-Lin
    Xu, Biao
    Kang, Li-Na
    ACTA DIABETOLOGICA, 2018, 55 (05) : 429 - 441
  • [8] Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials
    Xiao-Wen Zhang
    Xin-Lin Zhang
    Biao Xu
    Li-Na Kang
    Acta Diabetologica, 2018, 55 : 429 - 441
  • [9] An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin
    Evans, Marc
    Billings, Liana K.
    Hakan-Bloch, Jonas
    Slothuus, Ulla
    Abrahamsen, Trine J.
    Andersen, Andreas
    Jansen, Jeroen P.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (04) : 340 - 347
  • [10] A SHORT-TERM COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE U100 AND INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN
    Zhou, L.
    Zhou, N.
    Hu, M.
    VALUE IN HEALTH, 2022, 25 (07) : S386 - S386
12345